Foresight Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $316.25M |
|---|---|
| IPO Date | Feb 10, 2021 |
| CEO | Michael Balkin |
| Left Lead | Cowen |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Consumer
Technology-enabled consumer or consumer healthcare |
| IPO Geography | Global |
| Target Company | P3 Health Partners |
| Deal Announced | May 25, 2021 |
| Deal Size, $M | $2,336.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Dec 3, 2021 |
| Amendment Vote | TBD |
| Closing Date | Dec 3, 2021 |
Formerly FORE
PIII
PIIIW
| Price | $0.20 |
|---|---|
| Last closing price | $0.21 |
| H/L, today | $0.19 / $0.25 |
| H/L, 52-week | $0.70 / $5.76 |
| Volume, today | 2,212,119 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Foresight Acquisition Corp.:
- Structure and cap table
- 11 directors & officers
- 25 filings and events
- 1 underwriters
- 6 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Greg Wasson | 62 | Chairman |
| Michael Balkin | 61 | CEO and Director |
| Gerald Muizelaar | 46 | CFO |
| Brian Gamache | 62 | Director |
| Robert Zimmerman | 69 | Director |
| John Svoboda | 63 | Director |
| Mark Thierer | Advisor | |
| Kermit Crawford | Advisor | |
| Matt Shattock | Advisor | |
| Theodore Koenig | Advisor | |
| Craig Zummer | Advisor |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cowen | BR | 27,500,000 | units |
| 27,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| BCMA | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.